EUCTR2006-004507-18-FR进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® and RAD001 10 mg/d or Sandostatin LAR® and placebo - N/A
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Advanced (unresectable or metastatic) biopsy-proven carcinoid tumor
- •Patients must have confirmed low-grade or intermediate-grade neuroendocrine carcinoma
- •2. Patients must have radiological documentation of progression of disease within 12 months prior to randomization
- •3. Measurable disease per RECIST determined by Triphasic Computer Tomography (CT) scan or MRI
- •4. Adequate bone marrow function as shown by: ANC = 1.5 x 10 high 9/L, Platelets = 100 x 10 high 9/L, Hb >9 g/dL
- •5. Adequate liver function as shown by:
- •serum bilirubin = 1.5 x ULN
- •INR < 1.3
- •ALT and AST = 2.5x ULN (= 5x ULN in patients with liver metastases)
- •6. Adequate renal function: serum creatinine = 1.5 x ULN
- •7. Fasting serum cholesterol =300 mg/dL OR 7.75 mmol/L AND fasting triglycerides = 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
- •8. Performance Status 0-2 on the WHO scale
- •9. Adult male or female patients >18 years of age
- •10. Women of childbearing potential must have had a negative serum or urine pregnancy test 48 hours prior to the administration of the first study treatment.
- •11. Patients who give a written informed consent obtained according to local guidelines
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma are not eligible
- •2. Cytotoxic chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to randomization
- •3. Received treatment with Sandostatin LAR® Depot or any other long-acting somatostatin analog within 2 weeks prior to randomization.
- •4. Hepatic artery embolization within the last 6 months (1 month if there are other sites of measurable disease), or cryoablation of hepatic metastasis within 2 months of randomization
- •5. Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus)
- •6. Known intolerance or hypersensitivity to octreotide, Sandostatin LAR, RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus)
- •7. Uncontrolled diabetes mellitus as defined by fasting serum glucose >1.5 X ULN
- •8. Patients who have any severe and/or uncontrolled medical conditions such as:
- •unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months prior to randomization, serious uncontrolled cardiac arrhythmia
- •active or uncontrolled severe infection
- •cirrhosis, chronic active hepatitis or chronic persistent hepatitis
- •severely impaired lung function
- •9. Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent
- •10. Patients with a known history of HIV seropositivity
- •11. Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)
- •12. Patients who have a history of another primary malignancy = 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
- •13. Female patients who are pregnant or nursing (lactating), or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a InhibitorsMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-002126-36-ESF. Hoffmann-La Roche Ltd204
进行中（未招募）
1 期
Efficacy and safety study evaluating a new sublingual treatment in HDM allergic rhinitisHouse dust mite allergic rhinitisMedDRA version: 18.0Level: LLTClassification code 10001725Term: Allergic rhinitis due to other allergenSystem Organ Class: 100000004855EUCTR2014-004223-46-ESStallergenes S.A.990
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of Ritalin® LA in adult patients with childhood-onset ADHDAdult patients with childhood-onset Attention Deficit Hyperactivity DisorderMedDRA version: 12.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003736Term: Attention deficit/hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003737Term: Attention deficit/hyperactivity disorder NOSMedDRA version: 12.1Level: PTClassification code 10003736Term: Attention deficit/hyperactivity disorderEUCTR2010-021533-31-DKovartis Pharma Services AG700
进行中（未招募）
1 期
Safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyDiabetic nephropathyMedDRA version: 16.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersEUCTR2012-004179-38-NLBayer HealthCare AG823
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an antibody targeting certain types of immune cells, in Patients with Lupus NephritisEUCTR2015-002022-39-FRF. Hoffmann-La Roche Ltd125